Antitumor activity and a tolerable safety profile were observed for VERU-111, a novel tubulin inhibitor, to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who previously failed an androgen receptor (AR)–targeting agent, according to data from a phase 1b study presented at the 2021 Genitourinary Cancers Symposium.1
In 10 men who reached at least four 21-day cycles of continuous dosing with VERU-111, 6 experienced a decline in prostate-specific antigen (PSA). Moreover, 4 obtained a 30% or greater decline in PSA and 2 had a 50% or greater decline in PSA.
Two men experienced partial responses and 8 men experienced stable disease as best objective tumor response. Two additional objective responses occurred in patients who did not reach 4 cycles of continuous dosing.
The median duration of treatment without progression was greater than 11 months (range,…